Skip to content

The Delivery Strategies for PROTAC.

Sep 2026 · Handbook of Experimental Pharmacology · 0 citations
Medicine

TL;DR

This chapter systematically examines three progressive tiers of PROTAC delivery using stimuli-activatable moieties, and highlights how these strategies achieve spatiotemporally controlled, tumor-selective protein degradation while minimizing off-tumor toxicity.

View source

Similar papers

Review Open access Aug 2026

PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives

This review summarizes recent advances in chemical protein degradation strategies for neurodegenerative disorders and highlights potential future perspectives of multifunctional PROTACs for therapeutic development.

Pasquale Degennaro, Imane Ghafir El Idrissi, Rosa Purgatorio et al. · 0 citations
Review Sep 2026

BioPROTACs: a promising approach for targeted protein degradation.

The molecular mechanisms, recent advances, and emerging applications of bioPROTAC technology are summarized, the current technical challenges are evaluated, potential strategies to address these limitations are discussed, and future directions that may facilitate its clinical translation are highlighted.

Yu-Yang Li, Fu-Ru Zhang, Ren-Shuai Zhang et al. · 0 citations
Review Sep 2026

Nanoparticle-Based Delivery Strategies for Targeted Protein Degradation.

Targeted protein degradation (TPD) has fundamentally redefined pharmacological intervention, shifting from classical occupancy-driven inhibition to event-driven elimination of undruggable pathogenic proteins, holding great promise for treating various intractable diseases. Although heterobifunctional degraders and mole...

Le-Yuan Wang, Jian-Hui Yang, Yang Liu et al. · 0 citations
Review Open access Aug 2026

Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation

This critical review is an outline of all lipid, polymeric, inorganic, biomimetic, targeted, activatable, and self-assembling delivery systems for TPD, and assess compositional considerations, in vitro and in vivo evidence, challenges for translation, and clinical endpoints required to support delivery-enabled degradat...

Adnan Amin, Touseef Nawaz, Oberdan Oliveira Ferreira et al. · 0 citations
Review Open access Sep 2026

Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation

Advances establish PROTAC technology as a transformative platform in modern drug discovery while emphasizing the scientific and translational challenges that must be addressed to enable broader clinical application.

S. Badadhe, Vikas B. Gawali, Mahesh D. Bhalsing et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.